Form 4 for GILD Gilead Sciences
Accepted 2026-06-11 18:29:51 ET · period of report 2026-06-10 · accession 0001638643-26-000024 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-11 18:29 | 2026-06-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | +8,779 | 626.3K | +1% | — |
| D | 2026-06-11 18:29 | 2026-06-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | F - Tax | $121.48 | -4,213 | 622.1K | -0.7% | -$511.8K |
| D | 2026-06-11 18:29 | 2026-06-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | -8,779 | 92.1K | -9% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-10 | M | A | 8,779 | — | 626,346 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2026-06-10 | F | D | 4,213 | $121.48 | 622,133 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2026-06-10 | M | D | 8,779 | — | 92,080 | D | — · — to — | 8,779 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |